Search

Displaying results 3461 - 3470 of 6835 in total
  1. Drug

    Toripalimab

    go.drugbank.com/drugs/DB15043
    ApprovedInvestigational

    One mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the inhibition … The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance.

  2. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant … Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis [L1295].

  3. Drug

    Gadoversetamide

    go.drugbank.com/drugs/DB00538
    Approved

    Gadoversetamide, marketed under the trade name OptiMARK, is a gadolinium compound used as a contrast agent in magnetic resonance imaging (MRI), particularly imaging of the brain, spine and liver.

  4. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    [L11100] Clinical trials are expected to begin in 2020.[L11103,L11100] … It was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019.

  5. Drug

    Lipoic acid

    go.drugbank.com/drugs/DB00166
    ApprovedInvestigationalNutraceutical

    A vitamin-like antioxidant.

    Mixtures: Protect Plus SO 60Products: THIOCTACID 600 T
  6. Drug

    Dapoxetine

    go.drugbank.com/drugs/DB04884
    Investigational

    In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. … In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    12 years and older to be approved by the FDA. … [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who

  8. Drug

    Bupivacaine

    go.drugbank.com/drugs/DB00297
    ApprovedInvestigational

    Bupivacaine is a widely used local anesthetic agent.

  9. Drug

    Lactitol

    go.drugbank.com/drugs/DB12942
    Approved

    [A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.[L11803]

  10. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. … Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.